CASE DISCUSSION
High flow Nasal oxygen in Acute Respiratory Failure
Presented from India by Dr. Fernando Suparregui DiasViews
6,726
0
Credit Points
0
Learning Hours
0
CPD/CME Points
0
Courses Completed
Case Description
High flow nasal oxygen (HFNO) therapy represents a significant advancement in the management of acute respiratory failure, offering a blend of heated and humidified oxygen at high flow rates through nasal cannulae. This innovative approach enhances patient comfort, reduces the need for invasive...
Case Summary
- Oxygen's discovery 2.2 billion years ago was vital for life on Earth, essential for human metabolic function. Hypoxia, resulting from inadequate oxygenation, remains a leading cause of death in critical patients.
Speaker Profile
Dr. Fernando Suparregui Dias
Alumni- Brazilian Intensive Care AssociationCouncil Member , World Federation of Intensive Critical Care, Brazil.
Prof. Fernando Suparregui Dias is a renowned Professor of Medicine with extensive expertise in critical care and cardiovascular medicine. His professional work spans clinical practice, academic leadership, and advanced research focused on critical illness, personalized medicine, and intensive care outcomes.
He has significant experience in clinical and genomic research, data management in critical care, and translational medicine integrating molecular biology with bedside clinical practice. Prof. Dias is also recognized for implementing avatar-based patient monitoring systems to enhance situational awareness and clinical decision-making in intensive care units.
His academic interests include cardiology, circulatory shock, hemodynamic monitoring, and difficult airway management. In addition, he is actively involved in mentoring healthcare professionals and contributing to simulation-based training and critical care education programs.
Disclosures
Assimilate requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity have been reviewed and mitigated. Others involved in the planning of this activity have no relevant financial relationships.